CSLLY News and Press, CSL Ltd ADR From 01/31/24

2024-01-31 17:20:05 ET Summary Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 bill...

Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options PR Newswire Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to pati...

2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...

2024-01-03 10:19:29 ET More on Pfizer The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Pfizer: Buy The Panic Drugmakers reportedly planning to raise p...

CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe PR Newswire -    Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. -   ...

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster PR Newswire Study conducted by Meiji Seika Pharma in Japan Dat...

CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance PR Newswire These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living wi...

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B PR Newswire HEMGENIX ® is the first and ...

2023-11-29 07:40:38 ET More on uniQure uniQure: AMT-130 Data And Other Catalysts In H2 2023 uniQure to cut over 50% of research projects in strategic review uniQure cleared to start U.S. trial for gene therapy Seeking Alpha’s Quant Rating on uniQure ...

2023-11-28 14:14:56 ET More on Arcturus, CSL, etc. CSL Limited: Positive Capital Return And Earnings Growth Expectations From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey Arcturus: COVID Vaccine Approval Shots In Japan And Europe Key ...